Deep Medicine Acquisition Confirms Funding To Extend Period To Consummate Initial Business Combination
Deep Medicine Acquisition Corp. (NASDAQ:DMAQ) (the "Company"), announced today that an aggregate of $1,265,000 has been deposited into the Company's trust account for its public shareholders, representing $0.10 per public share, which enables the Company to extend the period of time it has to consummate its initial business combination by three months from October 29, 2022 to January 29, 2023 (the "Extension"). The Extension is the first of up to two three-month extensions permitted under the Company's governing documents.